Director Stampacchia Buys $29.75M of Windward Bio IPO Shares at $17.00
WWB sits 18% above its 52-week low of $18.35.
Summary
Windward Bio director Otello Stampacchia's Omega funds bought 1.75M shares at $17.00 for $29.75M in the IPO, alongside a 3.59M-share preferred conversion into common stock.
Key Events · Ownership and Investor Activity · WWB
-
Director's Funds Buy $29.75M at IPO Price
Omega Fund VII and Omega Fund VIII each acquired 875,000 shares at $17.00 on 2026-11-16, totaling 1,750,000 shares for $29,750,000.
-
Preferred Converts 1:1 Into Common
Immediately prior to the IPO closing, 3,588,520 Series A and Series B preferred shares converted into common on a 1-to-1 basis, leaving the funds with zero preferred.
-
Post-Transaction Indirect Stake 8.93M Shares
Following the purchase and conversion, the Omega funds indirectly hold 8,927,040 common shares; the reporting person disclaims beneficial ownership beyond his pecuniary interest.
-
Follows $251.2M IPO and Sanofi Placement
The purchase came at the $17.00 IPO price set on 2026-11-12, in the same window as the IPO close and concurrent Sanofi private placement that raised $251.2M gross.
Analysis · WWB · Life Sciences
Why it matters: a fund affiliated with director Otello Stampacchia (Omega Fund VII and VIII) put $29.75M of real money into 1.75M shares at the $17.00 IPO price, an anchor order rather than an option exercise. The same filing shows 3.59M preferred shares converting 1:1 into common immediately before the IPO close, which is mechanical pre-IPO cleanup rather than new dilution. The purchase is the meaningful part: a board member buying at the offer price alongside the $251.2M IPO and Sanofi private placement shows insider alignment at the exact level outside investors paid.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, WWB was trading at $21.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $18.35 to $33.99. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.